SCHEMBL4233303

SCHEMBL4233303

O=c1c2ccc(C(F)(F)F)cc2nc(-c2ccccc2F)n1NCc1ccc(Br)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
MDM2 Q00987 1/20 0.47
PDE2A O00408 2/20 0.39
PDE10A Q9Y233 2/20 0.39
MAPT P10636 4/20 0.39
NPSR1 Q6W5P4 2/20 0.39
CYP1A2 P05177 4/20 0.39
CYP2C9 P11712 4/20 0.39
CYP2C19 P33261 4/20 0.39
CYP2D6 P10635 3/20 0.39
CYP3A4 P08684 3/20 0.39
F7 P08709 1/20 0.38
F3 P13726 1/20 0.38
CTSD P07339 2/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
POLB P06746 1/20 0.37
SMN1; SMN2 Q16637 5/20 0.37
HTT P42858 4/20 0.37
KDM4E B2RXH2 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4238635 0.91 ALDH1A1 (0.47) ALDH1A1MDM2PDE2APDE10ACYP1A2
SCHEMBL4238037 0.87 ALDH1A1 (0.52) ALDH1A1MDM2MAPTNPSR1CYP1A2
SCHEMBL4233248 0.86 ALDH1A1 (0.56) ALDH1A1MDM2MAPTNPSR1CYP1A2
SCHEMBL4233268 0.86 ALDH1A1 (0.58) ALDH1A1MDM2MAPTNPSR1CYP1A2
SCHEMBL4245933 0.83 ALDH1A1 (0.51) ALDH1A1MDM2PDE2APDE10ANPSR1
SCHEMBL4235794 0.82 ALDH1A1 (0.56) ALDH1A1MDM2MAPTNPSR1CYP1A2
SCHEMBL4233391 0.79 CYP1A2 (0.49) ALDH1A1MDM2MAPTNPSR1CYP1A2
SCHEMBL4233285 0.79 MAPT (0.55) ALDH1A1MAPTNPSR1CYP1A2CYP2C9
SCHEMBL4237393 0.79 ALDH1A1 (0.58) ALDH1A1MDM2MAPTNPSR1CYP1A2
SCHEMBL4242035 0.79 ALDH1A1 (0.65) ALDH1A1MDM2MAPTNPSR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 GRK5, PLAAT5, GPBAR1 ALDH1A1 3192/4885MDM2 4740/4885PDE2A 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.